{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T13:57:33Z","timestamp":1790776653484,"version":"4.1.0"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T00:00:00Z","timestamp":1376438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurogastroenterology Motil"],"published-print":{"date-parts":[[2013,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The pharmacological properties of otilonium bromide (<jats:styled-content style=\"fixed-case\">OB<\/jats:styled-content>) have been investigated using different experimental models, techniques, and conditions, and consequently, the results are not always easy to compare. The aim of the present work was to investigate the pharmacological properties of <jats:styled-content style=\"fixed-case\">OB<\/jats:styled-content> in human cultured colonic smooth muscle cells (<jats:styled-content style=\"fixed-case\">HCSMCs<\/jats:styled-content>), which is the main target of the drug \u2018<jats:italic>in vivo<\/jats:italic>\u2019. Rat colonic strips were used to confirm the pharmacological properties.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Human cultured colonic smooth muscle cells were studied using the calcium imaging technique. Microelectrodes and muscle bath experiments were performed in rat colonic strips.<\/jats:p><\/jats:sec><jats:sec><jats:title>Key Results<\/jats:title><jats:p>Otilonium bromide (<jats:styled-content style=\"fixed-case\">OB<\/jats:styled-content>) concentration dependently inhibited nifedipine\u2010sensitive calcium transients induced by <jats:styled-content style=\"fixed-case\">KC<\/jats:styled-content>l (<jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content><jats:sub>50<\/jats:sub>\u00a0=\u00a03.6\u00a0<jats:italic>\u03bc<\/jats:italic>M) and BayK8644 (<jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content><jats:sub>50<\/jats:sub>\u00a0=\u00a04.0\u00a0<jats:italic>\u03bc<\/jats:italic>M). All the following experiments were performed in the presence of nifedipine. In <jats:styled-content style=\"fixed-case\">HCSMC<\/jats:styled-content>, carbachol\u2010induced calcium transients were inhibited by <jats:styled-content style=\"fixed-case\">OB<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content><jats:sub>50<\/jats:sub>\u00a0=\u00a08.4\u00a0<jats:italic>\u03bc<\/jats:italic>M). Carbachol evoked 1\u2014a smooth muscle depolarization (10\u00a0mV) that was antagonized by 100\u00a0<jats:italic>\u03bc<\/jats:italic>M <jats:styled-content style=\"fixed-case\">OB<\/jats:styled-content>; and 2\u2014a contraction that was inhibited by <jats:styled-content style=\"fixed-case\">OB<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content><jats:sub>50<\/jats:sub>\u00a0=\u00a013.0\u00a0<jats:italic>\u03bc<\/jats:italic>M). \u2018Non\u2010nitrergic (L\u2010<jats:styled-content style=\"fixed-case\">NNA<\/jats:styled-content> 1\u00a0mM) non\u2010purinergic (<jats:styled-content style=\"fixed-case\">MRS<\/jats:styled-content>2500 1\u00a0<jats:italic>\u03bc<\/jats:italic>M)\u2019 conditions were used to elicit endogenous excitatory responses. Electrical field stimulation caused 1\u2014an atropine\u2010sensitive excitatory junction potential that was inhibited by <jats:styled-content style=\"fixed-case\">OB<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content><jats:sub>50<\/jats:sub>\u00a0=\u00a08.9\u00a0<jats:italic>\u03bc<\/jats:italic>M) and 2\u2014an atropine\u2010sensitive contraction that was inhibited by <jats:styled-content style=\"fixed-case\">OB<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content><jats:sub>50<\/jats:sub>\u00a0=\u00a07.3\u00a0<jats:italic>\u03bc<\/jats:italic>M). In <jats:styled-content style=\"fixed-case\">HCSMC<\/jats:styled-content>, neurokinin A (<jats:styled-content style=\"fixed-case\">NKA<\/jats:styled-content>) and CaCl<jats:sub>2<\/jats:sub> induced calcium transients that were inhibited by <jats:styled-content style=\"fixed-case\">OB<\/jats:styled-content> (<jats:styled-content style=\"fixed-case\">NKA<\/jats:styled-content>:<jats:styled-content style=\"fixed-case\"> EC<\/jats:styled-content><jats:sub>50<\/jats:sub>\u00a0=\u00a011.7\u00a0<jats:italic>\u03bc<\/jats:italic>M; CaCl<jats:sub>2<\/jats:sub>: <jats:styled-content style=\"fixed-case\">EC<\/jats:styled-content><jats:sub>50<\/jats:sub>\u00a0=\u00a017.5\u00a0<jats:italic>\u03bc<\/jats:italic>M).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions &amp; Inferences<\/jats:title><jats:p>Otilonium bromide causes inhibition of L\u2010\/T\u2010type calcium channels, muscarinic, and tachykininergic responses that acting together explain the pharmacological properties of the compound.<\/jats:p><\/jats:sec>","DOI":"10.1111\/nmo.12206","type":"journal-article","created":{"date-parts":[[2013,8,14]],"date-time":"2013-08-14T10:11:36Z","timestamp":1376475096000},"source":"Crossref","is-referenced-by-count":15,"title":["Mechanisms of action of otilonium bromide (<scp>OB<\/scp>) in human cultured smooth muscle cells and rat colonic strips"],"prefix":"10.1111","volume":"25","author":[{"given":"M.","family":"Mart\u00ednez\u2010Cutillas","sequence":"first","affiliation":[{"name":"Department of Cell Biology, Physiology and Immunology and Neurosciences Institute Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Gil","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Physiology and Immunology and Neurosciences Institute Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Gallego","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Physiology and Immunology and Neurosciences Institute Universitat Aut\u00f2noma de Barcelona Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Ma\u00f1\u00e9","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Physiology and Immunology and Neurosciences Institute Universitat Aut\u00f2noma de Barcelona Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. T.","family":"Mart\u00edn","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Physiology and Immunology and Neurosciences Institute Universitat Aut\u00f2noma de Barcelona Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Jim\u00e9nez","sequence":"additional","affiliation":[{"name":"Department of Cell Biology, Physiology and Immunology and Neurosciences Institute Universitat Aut\u00f2noma de Barcelona Barcelona Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Hep\u00e1ticas y Digestivas (CIBERehd) Instituto de Salud Carlos III Barcelona Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,8,14]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00397.x"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0928-4257(01)00020-1"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2011.04730.x"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00384-012-1598-0"},{"key":"e_1_2_10_6_1","first-page":"643","article-title":"A distribution study with (14)C\u2010otilonium bromide in the rat: evidence for selective tropism for large intestine after oral administration","volume":"28","author":"Evangelista S","year":"2000","journal-title":"Drug Metab Dispos"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00005370"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2004.00518.x"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00437.2009"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2004.00517.x"},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2010.01495.x"},{"key":"e_1_2_10_12_1","doi-asserted-by":"publisher","DOI":"10.1006\/phrs.1998.0340"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2012.168"},{"key":"e_1_2_10_14_1","article-title":"Mechanisms of action of Otilonium Bromide (OB) in human cultured smooth muscle cells and rat colonic strips","volume":"24","author":"Jimenez M","year":"2012","journal-title":"Neurogastroenterol Motil"},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2004.00603.x"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00510.2007"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(95)00808-X"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.145672"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2982.2011.01725.x"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0702363"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-007-7148-1"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjp.0701587"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00374945"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1053\/gast.2002.30346"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00532.2001"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2002.00348.x"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00152.2003"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2010.199034"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpgi.00022.2005"}],"container-title":["Neurogastroenterology &amp; Motility"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fnmo.12206","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/nmo.12206","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,2]],"date-time":"2023-10-02T22:13:55Z","timestamp":1696284835000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/nmo.12206"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8,14]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["10.1111\/nmo.12206"],"URL":"https:\/\/doi.org\/10.1111\/nmo.12206","archive":["Portico"],"relation":{},"ISSN":["1350-1925","1365-2982"],"issn-type":[{"value":"1350-1925","type":"print"},{"value":"1365-2982","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,8,14]]}}}